Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase III clinical trial data presented today at the XXI International Society on Thrombosis and Haemostasis (ISTH) Congress demonstrate that once-daily rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head comparison with enoxaparin, the current standard of care. Patients in the RECORD3 (REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and PE) study who were treated with rivaroxaban demonstrated a 49% relative risk reduction (RRR) (p less than 0.001) in the composite primary endpoint of deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and all-cause mortality compared to those treated with enoxaparin. A 62% reduction of risk (p=0.01) for developing major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death) - the secondary endpoint of the trial - was observed in the patients treated with rivaroxaban. Rivaroxaban also demonstrated a similarly low rate of major bleeding compared to enoxaparin (0.6% and 0.5%, respectively).

Rivaroxaban is an investigational, oral, once-daily direct Factor Xa inhibitor. It is an anticoagulant - a drug designed to prevent and treat blood clots - in advanced clinical development for the prevention and treatment of thrombosis in acute and chronic settings, enabling convenient administration in both the hospital and at home.

Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development L.L.C. (J&JPRD), and Bayer HealthCare AG.

Lead RECORD3 investigator, Michael R. Lassen, MD, of Hoersholm Hospital, University of Copenhagen, Denmark, commented: "The RECORD3 results are exciting, as they indicate that rivaroxaban may better meet the needs of many patients undergoing orthopaedic surgery. It's an important step for t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the development and sale of patented ... generics and active pharmaceutical ingredients (API) announced that ... Macrolide Facility (JCM) has passed the internal quality ...
... NEW YORK, Nov. 9, 2011 ... research report is available in its ... and Reimbursement in Europe - Reference ... to Innovative Drugs Pose Significant Challenge ...
Cached Medicine Technology:JCM Passes Internal Quality Assessment for Azithromycin API Production 2JCM Passes Internal Quality Assessment for Azithromycin API Production 3Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 2Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 3Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 4Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 5Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 6Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 7
(Date:7/11/2014)... -- Delaying surgery to repair damage to the anterior cruciate ... the knee -- could increase a young athlete,s risk for ... of 130 patients, aged 8 to 16, who had ACL ... six weeks after their injury, 37 had surgery six to ... three months after their injury. The youngsters who had ...
(Date:7/11/2014)... VA (PRWEB) July 11, 2014 Riverside Health ... Care (CBCC) in Virginia in late 2012 and now, ... ChooseHome – to residents throughout the Williamsburg and Newport News ... programs provide services and benefits to independent older adults who ... access to a safety net of continuing care services as ...
(Date:7/11/2014)... For many years scientists have been trying to unravel ... cells, those cells that generate all blood cells including ... cells is difficult because they can only be found ... be recapitulated in a culture dish. Now a group ... Prof. Claudia Waskow (Technische Universitt Dresden) was able to ...
(Date:7/11/2014)... 2014 WWTrek Human Outreach Project ... Community in Tanzania. Opened in 2012, the KKC is now ... cows. HOP Founder, Dean Cardinale, started the KKC to create ... orphaned children he encountered while running treks on Tanzania's Mount ... who have all made astounding progress in school over the ...
(Date:7/11/2014)... New research from UC San Francisco shows that ... Medea Project helps women living with HIV disclose ... self-efficacy and the safety and quality of their ... study,s first author, Edward L. Machtinger, MD, director ... 90 percent of our patients are on effective ...
Breaking Medicine News(10 mins):Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Opening-up the stem cell niche 2Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:'Expressive therapy" intervention assists women living with HIV 2
... Transplant Week to raise awareness of the growing imbalance between ... number of people// awaiting transplants. ,Statistics show that ... joined the Organ Donor Register. In addition it has been ... 2,200 actually operations took place. ,The NHS has ...
... of the fetus is more accurately detected by ultra sound ... that Rh diseases of the fetus are more accurately detected ... blood flow in the middle cerebral artery, which is the ... were of the feeling that as ultrasound is an non-invasive ...
... said that around 176 babies are born each minute ... of World Population Day//. The program was organized by ... Grameen Arogya Abhiyan in Bangalore. ,"With the increase ... Population should be controlled in the interest of a ...
... large-scale study published in the July issue of the urology ... use of Uprima// , a drug known to treat problems ... rates of this drug. ,And 70 per cent ... National Health Service (NHS) drug feedback form felt the drug ...
... early as possible in an effort to reverse its ... leading// cause of disability in people over the age ... have been able to treat the disease and offer ... identified telltale, genetic signs that indicate the early onset ...
... the release of salaries of doctors participating in the anti-quota stir ... that the order to do so was issued on the direction ... V P Gupta, who was asked to explain the reason behind ... Venugopal., ,Gupta was asked to relinquish charge as Registrar by ...
Cached Medicine News:Health News:National Transplant Week to Raise Need for Organ Donation 2Health News:Doppler USG-Safer Technique For Detection Of Rh Diseases In Fetus 2Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 2Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 3Health News:Researchers Beginning to Identify Genetic Culprits of Arthritis 2
Adson bipolar forceps, 12 cm, straight....
Straight, blunt and pointed tips....
Angulated, blunt and pointed tips....
Blunt, 20 cm long....
Medicine Products: